Vasculitis Treatment Market By Drug Class (Biologics, Corticosteroids and immunosuppressants), By Disease Type (Small and medium vessel vasculitis, Large vessel vasculitis), By Distribution Channel (Hospital pharmacies, Drug store and retail pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031
Vasculitis causes inflammation of the blood vessels. Blood vessel walls may thicken as a result of the inflammation, reducing the diameter of the vessel's passage. Vasculitis is the inflammation of capillaries, veins, and arteries. The illness has no age restrictions and can affect both sexes equally. There are many different types of vasculitis, and their scientific characteristics might differ greatly in terms of severity, symptoms, and disease duration. The type of vasculitis differs depending on which blood vessels are affected.
The major factors that drive the growth of the vasculitis treatment market is increase in geriatric population, and rise in incidence of chronic diseases. In addition, shift toward the adoption rate of biologics and its development is a key trend of the market which is expected to fuel the market growth during the forecast period.
Many key market players are investing in R&D activities and launching new biologics products for the treatment of vasculitis. Various inorganic strategies, such as acquisition, are adopted by the key market players for expansion of the vasculitis treatment market. For instance, in August 2022 Amgen and ChemoCentryx, a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx.
In addition, the global demand for vasculitis treatment has increased as a result of the rise in the development of drugs and R&D activities related to them, which is a major driving force behind the growth of the vasculitis treatment market. However, side effects associated with usage of corticosteroids are expected to hinder the growth of the market. Conversely, rise in R&D activities for drug discovery and development to suffice the consumer demands in developing countries is expected to provide a great opportunity for the investors to invest in the market.
The global vasculitis treatment market is segmented on the basis of drug class, disease type, distribution channel, and region. On the basis of drug class, the market is categorized into biologics, corticosteroids, and immunosuppressants. As per disease type, it is divided into small & medium vessel vasculitis, and large vessel vasculitis. Small & medium vessel vasculitis is further bifurcated as ANCA associated vasculitis and others. Depending on distribution channel, the market is classified into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major players profiled in the report are AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, InflaRx NV, Novartis AG, Pfizer Inc., Staidson Biopharma Inc., and Teva Pharmaceuticals Industries Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vasculitis treatment market analysis from 2021 to 2031 to identify the prevailing vasculitis treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the vasculitis treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global vasculitis treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Distribution Channel
Hospital pharmacies
Drug store and retail pharmacies
Online Pharmacies
By Drug Class
Corticosteroids and immunosuppressants
Biologics
By Disease Type
Small and medium vessel vasculitis
Type
ANCA associated vasculitis
Others
Large vessel vasculitis
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest Of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA
Key Market Players
Amneal Pharmaceuticals, Inc.
AstraZeneca plc
F. Hoffmann-La Roche Ltd
Glaxosmithkline plc
Pfizer Inc.
InflaRx N.V
Novartis AG
ChemoCentryx
AbbVie
Teva Pharmaceutical Industries Ltd.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- 3.7.Patent Landscape
- CHAPTER 4: VASCULITIS TREATMENT MARKET, BY DRUG CLASS
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Biologics
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Corticosteroids and immunosuppressants
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- CHAPTER 5: VASCULITIS TREATMENT MARKET, BY DISEASE TYPE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Small and medium vessel vasculitis
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.2.4 Small and medium vessel vasculitis Vasculitis Treatment Market by Type
- 5.2.4.1 ANCA associated vasculitis Market size and forecast, by region
- 5.2.4.2 Others Market size and forecast, by region
- 5.3 Large vessel vasculitis
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- CHAPTER 6: VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Drug store and retail pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Online Pharmacies
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: VASCULITIS TREATMENT MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug Class
- 7.2.3 North America Market size and forecast, by Disease Type
- 7.2.3.1 North America Small and medium vessel vasculitis Vasculitis Treatment Market by Type
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Drug Class
- 7.2.5.1.2 Market size and forecast, by Disease Type
- 7.2.5.1.3 Market size and forecast, by Distribution Channel
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Drug Class
- 7.2.5.2.2 Market size and forecast, by Disease Type
- 7.2.5.2.3 Market size and forecast, by Distribution Channel
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Drug Class
- 7.2.5.3.2 Market size and forecast, by Disease Type
- 7.2.5.3.3 Market size and forecast, by Distribution Channel
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug Class
- 7.3.3 Europe Market size and forecast, by Disease Type
- 7.3.3.1 Europe Small and medium vessel vasculitis Vasculitis Treatment Market by Type
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Drug Class
- 7.3.5.1.2 Market size and forecast, by Disease Type
- 7.3.5.1.3 Market size and forecast, by Distribution Channel
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Drug Class
- 7.3.5.2.2 Market size and forecast, by Disease Type
- 7.3.5.2.3 Market size and forecast, by Distribution Channel
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Drug Class
- 7.3.5.3.2 Market size and forecast, by Disease Type
- 7.3.5.3.3 Market size and forecast, by Distribution Channel
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Drug Class
- 7.3.5.4.2 Market size and forecast, by Disease Type
- 7.3.5.4.3 Market size and forecast, by Distribution Channel
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Drug Class
- 7.3.5.5.2 Market size and forecast, by Disease Type
- 7.3.5.5.3 Market size and forecast, by Distribution Channel
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Drug Class
- 7.3.5.6.2 Market size and forecast, by Disease Type
- 7.3.5.6.3 Market size and forecast, by Distribution Channel
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
- 7.4.3 Asia-Pacific Market size and forecast, by Disease Type
- 7.4.3.1 Asia-Pacific Small and medium vessel vasculitis Vasculitis Treatment Market by Type
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Drug Class
- 7.4.5.1.2 Market size and forecast, by Disease Type
- 7.4.5.1.3 Market size and forecast, by Distribution Channel
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Drug Class
- 7.4.5.2.2 Market size and forecast, by Disease Type
- 7.4.5.2.3 Market size and forecast, by Distribution Channel
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Drug Class
- 7.4.5.3.2 Market size and forecast, by Disease Type
- 7.4.5.3.3 Market size and forecast, by Distribution Channel
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Drug Class
- 7.4.5.4.2 Market size and forecast, by Disease Type
- 7.4.5.4.3 Market size and forecast, by Distribution Channel
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Drug Class
- 7.4.5.5.2 Market size and forecast, by Disease Type
- 7.4.5.5.3 Market size and forecast, by Distribution Channel
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Drug Class
- 7.4.5.6.2 Market size and forecast, by Disease Type
- 7.4.5.6.3 Market size and forecast, by Distribution Channel
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug Class
- 7.5.3 LAMEA Market size and forecast, by Disease Type
- 7.5.3.1 LAMEA Small and medium vessel vasculitis Vasculitis Treatment Market by Type
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Drug Class
- 7.5.5.1.2 Market size and forecast, by Disease Type
- 7.5.5.1.3 Market size and forecast, by Distribution Channel
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Drug Class
- 7.5.5.2.2 Market size and forecast, by Disease Type
- 7.5.5.2.3 Market size and forecast, by Distribution Channel
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Drug Class
- 7.5.5.3.2 Market size and forecast, by Disease Type
- 7.5.5.3.3 Market size and forecast, by Distribution Channel
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Drug Class
- 7.5.5.4.2 Market size and forecast, by Disease Type
- 7.5.5.4.3 Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Amneal Pharmaceuticals, Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 AstraZeneca plc
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 F. Hoffmann-La Roche Ltd
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Glaxosmithkline plc
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Pfizer Inc.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 InflaRx N.V
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Novartis AG
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 ChemoCentryx
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 AbbVie
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Teva Pharmaceutical Industries Ltd.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 2. VASCULITIS TREATMENT MARKET, FOR BIOLOGICS, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. VASCULITIS TREATMENT MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. VASCULITIS TREATMENT MARKET, FOR CORTICOSTEROIDS AND IMMUNOSUPPRESSANTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. VASCULITIS TREATMENT MARKET FOR CORTICOSTEROIDS AND IMMUNOSUPPRESSANTS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. GLOBAL VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 7. VASCULITIS TREATMENT MARKET, FOR SMALL AND MEDIUM VESSEL VASCULITIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 8. VASCULITIS TREATMENT MARKET FOR SMALL AND MEDIUM VESSEL VASCULITIS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 9. GLOBAL SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 10. VASCULITIS TREATMENT MARKET, FOR ANCA ASSOCIATED VASCULITIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. VASCULITIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. VASCULITIS TREATMENT MARKET, FOR LARGE VESSEL VASCULITIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 13. VASCULITIS TREATMENT MARKET FOR LARGE VESSEL VASCULITIS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 14. GLOBAL VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 15. VASCULITIS TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. VASCULITIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. VASCULITIS TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. VASCULITIS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 19. VASCULITIS TREATMENT MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 20. VASCULITIS TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 21. VASCULITIS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 22. NORTH AMERICA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 23. NORTH AMERICA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 24. NORTH AMERICA SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 25. NORTH AMERICA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 26. NORTH AMERICA VASCULITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 27. U.S. VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 28. U.S. VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 29. U.S. VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 30. CANADA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 31. CANADA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 32. CANADA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 33. MEXICO VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 34. MEXICO VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 35. MEXICO VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 36. EUROPE VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 37. EUROPE VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 38. EUROPE SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 39. EUROPE VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 40. EUROPE VASCULITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 41. GERMANY VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 42. GERMANY VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 43. GERMANY VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 44. FRANCE VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 45. FRANCE VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 46. FRANCE VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 47. UK VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 48. UK VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 49. UK VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 50. ITALY VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 51. ITALY VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 52. ITALY VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 53. SPAIN VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 54. SPAIN VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 55. SPAIN VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 56. REST OF EUROPE VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 57. REST OF EUROPE VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 58. REST OF EUROPE VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 59. ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 60. ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 61. ASIA-PACIFIC SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 62. ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 63. ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 64. JAPAN VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 65. JAPAN VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 66. JAPAN VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 67. CHINA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 68. CHINA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 69. CHINA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 70. INDIA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 71. INDIA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 72. INDIA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 73. AUSTRALIA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 74. AUSTRALIA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 75. AUSTRALIA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 76. SOUTH KOREA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 77. SOUTH KOREA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 78. SOUTH KOREA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 79. REST OF ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 80. REST OF ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 81. REST OF ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 82. LAMEA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 83. LAMEA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 84. LAMEA SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 85. LAMEA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 86. LAMEA VASCULITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 87. BRAZIL VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 88. BRAZIL VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 89. BRAZIL VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 90. SAUDI ARABIA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 91. SAUDI ARABIA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 92. SAUDI ARABIA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 93. SOUTH AFRICA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 94. SOUTH AFRICA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 95. SOUTH AFRICA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 96. REST OF LAMEA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 97. REST OF LAMEA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 98. REST OF LAMEA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 99.AMNEAL PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
- TABLE 100.AMNEAL PHARMACEUTICALS, INC.: OPERATING SEGMENTS
- TABLE 101.AMNEAL PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
- TABLE 102.AMNEAL PHARMACEUTICALS, INC.: NET SALES,
- TABLE 103.AMNEAL PHARMACEUTICALS, INC.: KEY STRATERGIES
- TABLE 104.ASTRAZENECA PLC: COMPANY SNAPSHOT
- TABLE 105.ASTRAZENECA PLC: OPERATING SEGMENTS
- TABLE 106.ASTRAZENECA PLC: PRODUCT PORTFOLIO
- TABLE 107.ASTRAZENECA PLC: NET SALES,
- TABLE 108.ASTRAZENECA PLC: KEY STRATERGIES
- TABLE 109.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
- TABLE 110.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
- TABLE 111.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
- TABLE 112.F. HOFFMANN-LA ROCHE LTD: NET SALES,
- TABLE 113.F. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
- TABLE 114.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 115.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
- TABLE 116.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 117.GLAXOSMITHKLINE PLC: NET SALES,
- TABLE 118.GLAXOSMITHKLINE PLC: KEY STRATERGIES
- TABLE 119.PFIZER INC.: COMPANY SNAPSHOT
- TABLE 120.PFIZER INC.: OPERATING SEGMENTS
- TABLE 121.PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 122.PFIZER INC.: NET SALES,
- TABLE 123.PFIZER INC.: KEY STRATERGIES
- TABLE 124.INFLARX N.V: COMPANY SNAPSHOT
- TABLE 125.INFLARX N.V: OPERATING SEGMENTS
- TABLE 126.INFLARX N.V: PRODUCT PORTFOLIO
- TABLE 127.INFLARX N.V: NET SALES,
- TABLE 128.INFLARX N.V: KEY STRATERGIES
- TABLE 129.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 130.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 131.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 132.NOVARTIS AG: NET SALES,
- TABLE 133.NOVARTIS AG: KEY STRATERGIES
- TABLE 134.CHEMOCENTRYX: COMPANY SNAPSHOT
- TABLE 135.CHEMOCENTRYX: OPERATING SEGMENTS
- TABLE 136.CHEMOCENTRYX: PRODUCT PORTFOLIO
- TABLE 137.CHEMOCENTRYX: NET SALES,
- TABLE 138.CHEMOCENTRYX: KEY STRATERGIES
- TABLE 139.ABBVIE: COMPANY SNAPSHOT
- TABLE 140.ABBVIE: OPERATING SEGMENTS
- TABLE 141.ABBVIE: PRODUCT PORTFOLIO
- TABLE 142.ABBVIE: NET SALES,
- TABLE 143.ABBVIE: KEY STRATERGIES
- TABLE 144.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 145.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
- TABLE 146.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 147.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
- TABLE 148.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.VASCULITIS TREATMENT MARKET SEGMENTATION
- FIGURE 2.VASCULITIS TREATMENT MARKET,2021-2031
- FIGURE 3.VASCULITIS TREATMENT MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.VASCULITIS TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.PATENT ANALYSIS BY COMPANY
- FIGURE 13.PATENT ANALYSIS BY COUNTRY
- FIGURE 14.VASCULITIS TREATMENT MARKET,BY DRUG CLASS,2021(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF BIOLOGICS VASCULITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDS AND IMMUNOSUPPRESSANTS VASCULITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 17.VASCULITIS TREATMENT MARKET,BY DISEASE TYPE,2021(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF LARGE VESSEL VASCULITIS VASCULITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 20.VASCULITIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES VASCULITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF DRUG STORE AND RETAIL PHARMACIES VASCULITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES VASCULITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 24.VASCULITIS TREATMENT MARKET BY REGION,2021
- FIGURE 25.U.S. VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 26.CANADA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 27.MEXICO VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 28.GERMANY VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 29.FRANCE VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 30.UK VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 31.ITALY VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 32.SPAIN VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 33.REST OF EUROPE VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 34.JAPAN VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 35.CHINA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 36.INDIA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 37.AUSTRALIA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 38.SOUTH KOREA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 39.REST OF ASIA-PACIFIC VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 40.BRAZIL VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 41.SAUDI ARABIA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 42.SOUTH AFRICA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 43.REST OF LAMEA VASCULITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 48.COMPETITIVE DASHBOARD
- FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 50.AMNEAL PHARMACEUTICALS, INC..: NET SALES ,($MILLION)
- FIGURE 51.ASTRAZENECA PLC.: NET SALES ,($MILLION)
- FIGURE 52.F. HOFFMANN-LA ROCHE LTD.: NET SALES ,($MILLION)
- FIGURE 53.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
- FIGURE 54.PFIZER INC..: NET SALES ,($MILLION)
- FIGURE 55.INFLARX N.V.: NET SALES ,($MILLION)
- FIGURE 56.NOVARTIS AG.: NET SALES ,($MILLION)
- FIGURE 57.CHEMOCENTRYX.: NET SALES ,($MILLION)
- FIGURE 58.ABBVIE.: NET SALES ,($MILLION)
- FIGURE 59.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook